Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging

M. Guttinger, F. Guidi, M. Chinol, E. Reali, F. Veglia, G. Viale, G. Paganelli, A. Corti, A. G. Siccardi

Research output: Contribution to journalArticlepeer-review


We have shown previously that T cells, tagged with biotinylated anti-CD3 antibody fragments, can exert avidin-dependent cytolytic activity on suitably biotinylated tumor cells in vitro. In this study, we demonstrate that avidin-driven CTL-tumor bridging in vivo leads to growth inhibition of murine tumors WEHI-164 fibrosarcoma and RMA lymphoma. The biodistribution of biotin-tagged 111In-labeled T cells demonstrated a selective avidin-dependent and time-dependent accumulation of radioactivity at tumor sites. The specificity of lymphocyte tumor localization was demonstrated by the concurrent time-dependent decrease of radioactivity in the blood and in all other organs. Furthermore, we documented a therapeutic effect of the adoptively transferred T cells, i.e., a significant delay of tumor growth at early stages. All of the experiments included a control group of mice, which received all of the reagents, except avidin. These avidin-minus mice showed no specific localization and no delay in tumor growth, indicating that avidin bridging was essential for T-cell activity at tumor sites.

Original languageEnglish
Pages (from-to)4211-4215
Number of pages5
JournalCancer Research
Issue number15
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging'. Together they form a unique fingerprint.

Cite this